

DAFTAR PUSTAKA

- Antunes NT, Lamoureaux TL, Toth M, Stewart NK, Frase H, Vakulenko SB. 2014. Class D β -lactamases: are they all carbapenemases?. *Antimicrob Agents Chemother.* 2014;58(4):2119-25
- Asif M, Alvi IA and Rehman SU. 2018. Insight into *Acinetobacter baumannii*: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. *Infection and Drug Resistance.* 11: 1249–1260.
- Berezin EB. Importance of *Acinetobacter spp.* 2008. In: E.Bergogne-Berezin *et al* (eds). *Acinetobacter Biology and pathogenesis.* Springer, New York. 1-14
- Bonnin RA, Nordmann P and Poirel L. 2013. Screening and deciphering antibiotic resistance in *Acinetobacter baumannii*: a state of the art. *Exp Rev Anti Infect Ther.* 11:571-583.
- Braun G. 2008. Virulence mechanisms of *Acinetobacter*. In: E.Bergogne-Berezin *et al* (eds). *Acinetobacter Biology and pathogenesis.* Springer, New York.145150
- Carvalhoes CG, Cayô R, Assis DM, Martins ER, Juliano L, Juliano MA, and Galesa CA. 2013. Detection of SPM-1-Producing *Pseudomonas aeruginosa* and Class D β -Lactamase-Producing *Acinetobacter baumannii* Isolates by Use of Liquid Chromatography-Mass Spectrometry and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry. *J Clin Microbiol.* 51(1): 287–290
- CDC. 2013. Antibiotic resistance threats in the United States
- CLSI. 2018. Performance standards for antimicrobial susceptibility testing. 28 ed. CLSI supplement M100. Wayne,PA: Clinical and Laboratory Standard Institute.
- Codjoe FS and Donkor ES. 2018. Carbapenem Resistance: A Review. *Med. Sci.* 6: 1-28
- Djahmi N, Dunyach-Remi C, Pantel A, Dekhil M, Sotto A, and Philippe Lavigne J. 2014. Epidemiologi of carbapenemase –producing *Enterobacteriaceae* and *Acinetobacter baumannii* in Mediterranean Countries. *Bio Med Research International.*
- Dortet L, Poirel L, Errera C and Nordmann P. 2014. CarbAcineto NP test for rapid detection of carbapenemase- producing *Acinetobacter spp.* *Journal of Clinical Microbiology.* 52(7): 2359–2364.
- Ellis D, Cohen B, Liu J and Larson E. 2015. Risk factors for hospital-acquired antimicrobial-resistant infection caused by *Acinetobacter baumannii*. *Antimicrobial Resistance and Infection Control.* 4: 40.

- Geisinger E, Isberg RR. 2015. Antibiotic modulation of capsular exopolysaccharide and virulence in *Acinetobacter baumannii*. PLoS Pathog 11(2)
- Handal R, Qunibi L, Sahouri I, Juhari M, Dawodi R, Marzouqa H, and Hindiye M. 2017. Characterization of carbapenem-resistant *Acinetobacter baumannii* strains isolated from hospitalized patients in Palestine. International Journal of Microbiology.
- Harding CM., Hennon SW, Feldman MF. 2018. Uncovering the mechanisms of *Acinetobacter baumannii* virulence. Nature Reviews. 16:91-102
- Héritier C., Poirel L., Nordman P. 2006. Cephalosporinase over-expression resulting from insertion of ISAbal in *Acinetobacter baumannii*. Clinical Microbiology and Infection.12(2):123-130.
- Héritier C., Poirel L., Nordman P. 2006. Cephalosporinase over-expression resulting from insertion of ISAbal in *Acinetobacter baumannii*. Clinical Microbiology and Infection.12(2):123-130.
- Howard A, O'Donoghue M, Feeney A and Sleato RD.2012. *Acinetobacter baumannii* an emerging opportunistic pathogen. Virulence 3:3, 243–250
- Hsu L-Y, Apisarnthanarak A, Khan E, Suwantararat N, Ghafur A, Tambyah PA. 2017. Carbapenem-resistant *Acinetobacter baumannii* and *Enterobacteriaceae* in South and Southeast Asia. Clin Microbiol Rev. 30:1–22.
- Jing X, Zhou H, Min X, Zhang X, Yang Q, Du S, Li Y, Yu F, Jia M, Zhan Y, Zeng Y, Yang B, Pan Y, Lu B, Liu R and Zeng J. 2018. The Simplified Carbapenem Inactivation Method (sCIM) for Simple and Accurate Detection of Carbapenemase-Producing Gram-Negative Bacilli. Front. Microbiol. 9:2391
- Kurniati ND, Wasito EB, Mertaniasih NM. 2016. Akurasi metode deteksi *CARB ACINETO NP* isolat darah mikroba *Acinetobacter baumannii* penghasil karbapenemase pasien rawat inap intensif. Karya Akhir. Program studi PPDS-1 Mikrobiologi Klinik. FK UNAIR. Surabaya
- Lee C-R, Lee JH, Park M, Park KS, Bae IK, Kim YB, Cha C-J, Jeong BC and Lee SH. 2017. Biology of *Acinetobacter baumannii*: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front. Cell. Infect. Microbiol. 7:55.
- Literacka E, Herda M, Baraniak A, Żabicka D, Hryniewicz W, Skoczyńska A, and Gniadkowski M. 2017. Evaluation of the Carba NP test for carbapenemase detection in *Enterobacteriaceae*, *Pseudomonas spp.* and *Acinetobacter spp.*, and its practical use in the routine work of a national reference laboratory for susceptibility testing. Eur J Clin Microbiol Infect Dis. 36: 2281–2287.

- Liu M, Song Q, Wu L, Li M, Chen Z, Kang M, Xie Y. 2018. Triton X-100 and increased volume of test bacteria in the carbapenem inactivation method enhanced the detection of carbapenemase-producing *Acinetobacter baumannii* complex isolates. *J Clin Microbiol* 56:1982-17
- Manchanda V, Sanchaita S and Singh NP. 2010. Multidrug resistant *Acinetobacter*. *J Global Infect Dis.* 2: 291-304.
- Maragakis L and Perl T. 2008. *Acinetobacter baumannii*: Epidemiology, Antimicrobial Resistance, and Treatment Options. *Clin Infect Dis.* 46:1254–63.
- Meletis G. 2016. Carbapenem resistance: overview of the problem and future perspectives. *Ther Adv Infect Dis.*3(1):15-21
- Mendes RE, Bell JM, Turnidge JD, Castanheira M, and Jones RN. 2008. Emergence and widespread dissemination of OXA-23,- 24/40 and -58 carbapenemases among *Acinetobacter* spp. in Asia-Pacific nations. *J Antimicrob Chemother.* 63(1):55-9
- Miller S, Humphries RM. 2016. Clinical laboratory detection of carbapenem-resistant and carbapenemase-producing Enterobacteriaceae. *Expert Rev Anti Infect Ther* 14:705–717.
- Ming Chen C., Chin Kec S., Ru Lid C., and Chin Chang C. 2014. The comparison of genotyping, antibiogram, and antimicrobial resistance genes between carbapenem-susceptible and resistant *Acinetobacter baumannii*. *Comparative Immunology, Microbiology and Infectious Diseases.* 37:339–346
- Moon, D. C., Choi, C. H., Lee, J. H., Choi, C. W., Kim, H. Y., Park, J. S. 2012. *Acinetobacter baumannii* outer membrane protein A modulates the biogenesis of outer membrane vesicles. *J.Microbiol.* 50, 155–160
- Nowak P and Paluchowska. 2016. *Acinetobacter baumannii*: biology and drug resistance – role carbapenemases. *Folia histochemica et cytobiologica.* 54(2):61-74
- Peleg AY, Seifert H, and Paterson DL. 2008. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev.* 21(3): 538-82.
- Perez P, Hujer, AM, Hujer KM, Decker BK, Rather PN, and Bonomo RA.2007. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy.* 51(10): 3471–3484.
- Playford E, Craig J and Iredell J. 2007. Carbapenem-resistant *Acinetobacter baumannii* in intensive care unit patients: risk factors for acquisition, infection and their consequences. *J Hosp Infect.* 65: 204–11.
- Porel L and Nordman P. Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. 2006. *Clin Microbiol Infect.*12: 826-36

- Saharman YS., Karuniawati A., Sedono R., Aditianingsih D, Sudarmono P, H. F. Goessens W, H.W. Klaassen C, Verbrugh HA and Severin JA. 2018. Antimicrobial Resistance and Infection Control .7:5
- Seifert and Dijkshoorn. Overview of the microbial characteristics, taxonomy, and epidemiology of *Acinetobacter*. In: E.Bergogne-Berezin *et al* (eds). *Acinetobacter* biology and pathogenesis. Springer, New York. 1-14
- Singh H, Th angaraj P, Chakrabarti A. 2013. *Acinetobacter baumannii*: a brief account of mechanisms of multidrug resistance and current and future therapeutic management. Journal of Clinical and Diagnostic Research. 2013 Nov, Vol-7(11): 2602-2605
- Smani, Y., Fabrega, A., Roca, I., Sanchez-Encinales, V., Vila, J., and Pachon, J. 2014. Role of OmpA in the multidrug resistance phenotype of *Acinetobacter baumannii*. Antimicrob. Agents Chemother. 58: 1806–1808
- Tamma PD and Simner P. 2018. Phenotypic detection of carbapenemase-producing organisms from Clinical Isolates. J. Clin. Microbiol.
- Tamma PD, Opene BNA, Gluck A, Chambers KK, Carroll KC, Simner PJ. 2017. Comparison of 11 phenotypic assays for accurate detection of carbapenemase producing *Enterobacteriaceae*. J Clin Microbiol 55:1046 –1055.
- Uechi K, Tada T, Shimada K, Kuwahara-Arai K, Arakaki M, Tome T, Nakasone I, Maeda S, Kirikae T, Fujita J. 2017. A modified carbapenem inactivation method, CIMTris, for carbapenemase production in *Acinetobacter* and *Pseudomonas* species. J Clin Microbiol 55: 3405–3410
- WHO. 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics
- Workneb M, Yee R, and Simner PJ. 2019. Phenotypic methods for detection of carbapenemase production in carbapenem-resistant organisms: what method should your laboratory choose?. Clinical microbiology newsletter.41:2
- Zarrilli R, Giannouli M, Tomasone F, Triassi M, and Tsakris A. 2009. Carbapenem resistance in *A. baumannii*: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries. 3(5): 335-41.